An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Trial Status: active
This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462
(also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu)
vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in
participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior
exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens
and to select the recommended dose of the combination for phase III. Towards that end,
the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from
participants randomized in the study will be evaluated.
Inclusion Criteria
Adult male participants with histologically and/or cytologically confirmed adenocarcinoma of the prostate. Participants with mixed histology (neuroendocrine) are not eligible.
An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) grade ≤2.
At least 1 bone or visceral metastatic lesion present on baseline CT, MRI, or bone scan imaging obtained ≤28 days prior to initiation of study treatment.
Participants must be [68Ga]Ga-PSMA-11 PET/CT scan positive and eligible as determined by the sponsor's central reader.
Participant must have prior exposure to at least one second generation ARPI in the metastatic/advanced setting.
Previous treatment with a maximum of 2 taxane regimens is allowed.
Participants eligible for PARPi and/or immune checkpoint inhibitor (per local testing and according to investigator's judgement) are eligible to participate if they have previous exposure to this(these) therapy(ies). Key
Exclusion Criteria
Prior treatment with any RLT (approved or investigational) is not allowed
Prior treatment with a protein degrader compound that targets AR is not allowed Other protocol-defined inclusion/exclusion criteria may apply.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07047118.
Locations matching your search criteria
United States
New York
New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: Active
Name Not Available
Pennsylvania
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: Active
Name Not Available
The study consists of a screening period, a randomization period, a treatment period, a
post-treatment safety follow-up followed by a long-term follow-up period.
JSB462 administration starts at day 1 of randomization, whereas AAA617 administration
starts at day 1 of treatment period. Participants in arm 1 and arm 2 will therefore
receive JSB462 during the 14-day randomization period before first administration of
AAA617.
- JSB462 is administered orally, daily and continuously (100 mg or 300 mg once a day
(QD)) until disease progression per Prostate Cancer Working Group (PCWG) 3-modified
Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by the
investigator, the occurrence of unacceptable toxicities, death, participant decision
or investigator decision.
- AAA617 will be administered at 7.4 gigabecquerel (GBq) intravenously every 6 weeks
for up to 6 doses, unless there is disease progression per PCWG3-modified RECIST
v1.1 as assessed by the investigator, the occurrence of unacceptable toxicities,
death, participant decision or investigator decision.
During the post-treatment follow up period:
- Safety follow-Up: After discontinuation of study treatment, all participants will be
followed for at least 1 safety follow-up visit (30 days [+/- 7 days] after end of
treatment visit). Subsequent lines of therapy may be administered according to
investigator's discretion after treatment discontinuation.
- Long-term follow-up: Starts after the Safety follow-up period and lasts until the
end of study. Safety, efficacy and survival information may be collected from the
participants during this period.
Trial PhasePhase II
Trial Typetreatment
Lead OrganizationNovartis Pharmaceuticals Corporation
